换肤

主营介绍

  • 主营业务:

    核苷类抗乙肝病毒药物的研发、生产与销售

  • 产品类型:

    医药制造、医学检验

  • 产品名称:

    抗乙肝病毒药物 、 保肝护肝药物 、 消化系统药物 、 呼吸系统药物 、 心血管药物 、 医学检验服务

  • 经营范围:

    凭药品生产许可证生产销售:片剂、胶囊剂、茶剂、颗粒剂、原料药、人工天竺黄;凭食品卫生许可证生产销售保健食品;出口:本企业自产的医药制品(医药行业有规定的从其规定);进口:本企业生产、科研所需的原辅材料、机械设备、零配件及技术的进口业务;药品、保健食品、食品的研发及提供相关技术服务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)

运营业务数据

最新公告日期:2020-03-26 
业务名称 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
医药制造(保肝护肝药物)库存量(片(粒/袋)) 2882.52万 3202.83万 - - -
医药制造(呼吸系统药物)库存量(片(粒/袋)) 126.41万 150.19万 - - -
医药制造(心血管药物)库存量(片(粒/袋)) 0.00 175.50万 - - -
医药制造(抗乙肝病毒药物)库存量(片(粒/袋)) 1485.86万 1078.67万 - - -
医药制造(消化系统药物)库存量(片(粒/袋)) 282.39万 304.86万 - - -
医药行业(阿甘定)库存量(片) - - 265.89万 694.60万 274.80万
医药行业(贺甘定)库存量(片) - - 136.26万 95.84万 153.11万
医药行业(恩甘定)库存量(片) - - 729.84万 477.10万 -
医药行业(福甘定)库存量(片) - - 48.26万 - -
医药行业(恩甘定)库存量(粒) - - - - 150.70万

主营构成分析

{"2019-12-31":{"YYSR":{"1":[["\u533b\u836f\u5236\u9020","41386.59"],["\u533b\u5b66\u68c0\u9a8c","91.46"]],"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","25817.62"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","13048.61"],["\u6d88\u5316\u7cfb\u7edf\u836f\u7269","1870.23"],["\u547c\u5438\u7cfb\u7edf\u836f\u7269","621.47"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",120.12]],"3":[["\u4e1c\u533a","16127.41"],["\u5317\u533a","13388.73"],["\u897f\u5317\u533a","4930.36"],["\u5357\u533a","4855.15"],["\u897f\u5357\u533a","2176.42"]]},"YYCB":{"1":[["\u533b\u836f\u5236\u9020","9209.09"],["\u533b\u5b66\u68c0\u9a8c",""]],"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","4869.10"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","2695.08"],["\u6d88\u5316\u7cfb\u7edf\u836f\u7269",""],["\u547c\u5438\u7cfb\u7edf\u836f\u7269",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u4e1c\u533a","3317.33"],["\u5317\u533a","3004.09"],["\u897f\u5317\u533a","1150.93"],["\u5357\u533a","1264.06"],["\u897f\u5357\u533a","603.39"]]},"LRBL":{"1":[["\u533b\u836f\u5236\u9020","100.00"],["\u533b\u5b66\u68c0\u9a8c",""]],"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","66.92"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","33.08"],["\u6d88\u5316\u7cfb\u7edf\u836f\u7269",""],["\u547c\u5438\u7cfb\u7edf\u836f\u7269",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u4e1c\u533a","39.86"],["\u5317\u533a","32.31"],["\u897f\u5317\u533a","11.76"],["\u5357\u533a","11.17"],["\u897f\u5357\u533a","4.89"]]}},"2019-06-30":{"YYSR":{"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","13945.15"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","6123.05"]],"3":[["\u4e1c\u533a","8520.47"],["\u5317\u533a","7250.84"],["\u897f\u5317\u533a","2458.04"],["\u5357\u533a","2282.54"],["\u897f\u5357\u533a","963.78"]]},"YYCB":{"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","2173.05"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","1249.88"]],"3":[["\u4e1c\u533a","1653.59"],["\u5317\u533a","1457.24"],["\u897f\u5317\u533a","546.11"],["\u5357\u533a","556.56"],["\u897f\u5357\u533a","256.58"]]},"LRBL":{"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","70.72"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","29.28"]],"3":[["\u4e1c\u533a","40.38"],["\u5317\u533a","34.07"],["\u897f\u5317\u533a","11.24"],["\u5357\u533a","10.15"],["\u897f\u5357\u533a","4.16"]]}},"2018-12-31":{"YYSR":{"1":[["\u533b\u836f\u5236\u9020","40218.92"],["\u533b\u5b66\u68c0\u9a8c","20.02"]],"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","33117.30"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","5967.94"],["\u6d88\u5316\u7cfb\u7edf\u836f\u7269","908.61"],["\u547c\u5438\u7cfb\u7edf\u836f\u7269","209.41"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",35.69]],"3":[["\u4e1c\u533a","15192.67"],["\u5317\u533a","13809.85"],["\u5357\u533a","4356.76"],["\u897f\u5317\u533a","4316.10"],["\u897f\u5357\u533a","2563.57"]]},"YYCB":{"1":[["\u533b\u836f\u5236\u9020","6580.91"],["\u533b\u5b66\u68c0\u9a8c",""]],"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","4504.49"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","1240.13"],["\u6d88\u5316\u7cfb\u7edf\u836f\u7269","717.73"],["\u547c\u5438\u7cfb\u7edf\u836f\u7269",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u4e1c\u533a","2333.88"],["\u5317\u533a","2118.90"],["\u5357\u533a","884.66"],["\u897f\u5317\u533a","794.74"],["\u897f\u5357\u533a","464.76"]]},"LRBL":{"1":[["\u533b\u836f\u5236\u9020","100.00"],["\u533b\u5b66\u68c0\u9a8c",""]],"2":[["\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","85.33"],["\u4fdd\u809d\u62a4\u809d\u836f\u7269","14.10"],["\u6d88\u5316\u7cfb\u7edf\u836f\u7269","0.57"],["\u547c\u5438\u7cfb\u7edf\u836f\u7269",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u4e1c\u533a","38.22"],["\u5317\u533a","34.75"],["\u5357\u533a","10.32"],["\u897f\u5317\u533a","10.47"],["\u897f\u5357\u533a","6.24"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u533b\u836f\u5236\u9020","timeData":["2019-12-31","2018-12-31"],"lineData":[41386.59,40218.92],"columnData":[99.78,99.95],"unit":["4.14\u4ebf","4.02\u4ebf"]},{"name":"\u533b\u5b66\u68c0\u9a8c","timeData":["2019-12-31","2018-12-31"],"lineData":[91.46,20.02],"columnData":[0.22,0.05],"unit":["91.46\u4e07","20.02\u4e07"]}],"chartWrap2":[{"name":"\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[25817.62,13945.15,33117.3],"columnData":[62.24,69.49,82.3],"unit":["2.58\u4ebf","1.39\u4ebf","3.31\u4ebf"]},{"name":"\u4fdd\u809d\u62a4\u809d\u836f\u7269","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[13048.61,6123.05,5967.94],"columnData":[31.46,30.51,14.83],"unit":["1.30\u4ebf","6123.05\u4e07","5967.94\u4e07"]},{"name":"\u6d88\u5316\u7cfb\u7edf\u836f\u7269","timeData":["2019-12-31","2018-12-31"],"lineData":[1870.23,908.61],"columnData":[4.51,2.26],"unit":["1870.23\u4e07","908.61\u4e07"]},{"name":"\u547c\u5438\u7cfb\u7edf\u836f\u7269","timeData":["2019-12-31","2018-12-31"],"lineData":[621.47,209.41],"columnData":[1.5,0.52],"unit":["621.47\u4e07","209.41\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-12-31","2018-12-31"],"lineData":[120.12,35.69],"columnData":[0.29,0.09],"unit":["120.12\u4e07","35.69\u4e07"]}],"chartWrap3":[{"name":"\u4e1c\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[16127.41,8520.47,15192.67],"columnData":[38.88,39.67,37.76],"unit":["1.61\u4ebf","8520.47\u4e07","1.52\u4ebf"]},{"name":"\u5317\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[13388.73,7250.84,13809.85],"columnData":[32.28,33.76,34.32],"unit":["1.34\u4ebf","7250.84\u4e07","1.38\u4ebf"]},{"name":"\u897f\u5317\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[4930.36,2458.04,4316.1],"columnData":[11.89,11.45,10.73],"unit":["4930.36\u4e07","2458.04\u4e07","4316.10\u4e07"]},{"name":"\u5357\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[4855.15,2282.54,4356.76],"columnData":[11.71,10.63,10.83],"unit":["4855.15\u4e07","2282.54\u4e07","4356.76\u4e07"]},{"name":"\u897f\u5357\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[2176.42,963.78,2563.57],"columnData":[5.25,4.49,6.37],"unit":["2176.42\u4e07","963.78\u4e07","2563.57\u4e07"]}]},"YYCB":{"chartWrap1":[{"name":"\u533b\u836f\u5236\u9020","timeData":["2019-12-31","2018-12-31"],"lineData":[9209.09,6580.91],"columnData":[100,100],"unit":["9209.09\u4e07","6580.91\u4e07"]},{"name":"\u533b\u5b66\u68c0\u9a8c","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]}],"chartWrap2":[{"name":"\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[4869.1,2173.05,4504.49],"columnData":[64.37,63.49,69.7],"unit":["4869.10\u4e07","2173.05\u4e07","4504.49\u4e07"]},{"name":"\u4fdd\u809d\u62a4\u809d\u836f\u7269","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[2695.08,1249.88,1240.13],"columnData":[35.63,36.51,19.19],"unit":["2695.08\u4e07","1249.88\u4e07","1240.13\u4e07"]},{"name":"\u6d88\u5316\u7cfb\u7edf\u836f\u7269","timeData":["2019-12-31","2018-12-31"],"lineData":[0,717.73],"columnData":[0,11.11],"unit":["0.00","717.73\u4e07"]},{"name":"\u547c\u5438\u7cfb\u7edf\u836f\u7269","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]}],"chartWrap3":[{"name":"\u4e1c\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[3317.33,1653.59,2333.88],"columnData":[35.52,36.99,35.38],"unit":["3317.33\u4e07","1653.59\u4e07","2333.88\u4e07"]},{"name":"\u5317\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[3004.09,1457.24,2118.9],"columnData":[32.16,32.6,32.12],"unit":["3004.09\u4e07","1457.24\u4e07","2118.90\u4e07"]},{"name":"\u897f\u5317\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[1150.93,546.11,794.74],"columnData":[12.32,12.22,12.05],"unit":["1150.93\u4e07","546.11\u4e07","794.74\u4e07"]},{"name":"\u5357\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[1264.06,556.56,884.66],"columnData":[13.53,12.45,13.41],"unit":["1264.06\u4e07","556.56\u4e07","884.66\u4e07"]},{"name":"\u897f\u5357\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[603.39,256.58,464.76],"columnData":[6.46,5.74,7.05],"unit":["603.39\u4e07","256.58\u4e07","464.76\u4e07"]}]},"LRBL":{"chartWrap1":[{"name":"\u533b\u836f\u5236\u9020","timeData":["2019-12-31","2018-12-31"],"lineData":[100,100],"columnData":[100,100],"unit":["100.00\u4e07","100.00\u4e07"]},{"name":"\u533b\u5b66\u68c0\u9a8c","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]}],"chartWrap2":[{"name":"\u6297\u4e59\u809d\u75c5\u6bd2\u836f\u7269","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[66.92,70.72,85.33],"columnData":[66.92,70.72,85.33],"unit":["66.92\u4e07","70.72\u4e07","85.33\u4e07"]},{"name":"\u4fdd\u809d\u62a4\u809d\u836f\u7269","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[33.08,29.28,14.1],"columnData":[33.08,29.28,14.1],"unit":["33.08\u4e07","29.28\u4e07","14.10\u4e07"]},{"name":"\u6d88\u5316\u7cfb\u7edf\u836f\u7269","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0.57],"columnData":[0,0.57],"unit":["0.00","5700.00"]},{"name":"\u547c\u5438\u7cfb\u7edf\u836f\u7269","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]}],"chartWrap3":[{"name":"\u4e1c\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[39.86,40.38,38.22],"columnData":[39.86,40.38,38.22],"unit":["39.86\u4e07","40.38\u4e07","38.22\u4e07"]},{"name":"\u5317\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[32.31,34.07,34.75],"columnData":[32.31,34.07,34.75],"unit":["32.31\u4e07","34.07\u4e07","34.75\u4e07"]},{"name":"\u897f\u5317\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[11.76,11.24,10.47],"columnData":[11.76,11.24,10.47],"unit":["11.76\u4e07","11.24\u4e07","10.47\u4e07"]},{"name":"\u5357\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[11.17,10.15,10.32],"columnData":[11.17,10.15,10.32],"unit":["11.17\u4e07","10.15\u4e07","10.32\u4e07"]},{"name":"\u897f\u5357\u533a","timeData":["2019-12-31","2019-06-30","2018-12-31"],"lineData":[4.89,4.16,6.24],"columnData":[4.89,4.16,6.24],"unit":["4.89\u4e07","4.16\u4e07","6.24\u4e07"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 医药制造 4.14亿 99.78% 9209.09万 100.00% 100.00% 77.75%
医学检验 91.46万 0.22% - - - -
按产品 抗乙肝病毒药物 2.58亿 62.24% 4869.10万 64.37% 66.92% 81.14%
保肝护肝药物 1.30亿 31.46% 2695.08万 35.63% 33.08% 79.35%
消化系统药物 1870.23万 4.51% - - - -
呼吸系统药物 621.47万 1.50% - - - -
医学检验服务 91.46万 0.22% - - - -
心血管药物 28.66万 0.07% - - - -
按地区 东区 1.61亿 38.88% 3317.33万 35.52% 39.86% 79.43%
北区 1.34亿 32.28% 3004.09万 32.16% 32.31% 77.56%
西北区 4930.36万 11.89% 1150.93万 12.32% 11.76% 76.66%
南区 4855.15万 11.71% 1264.06万 13.53% 11.17% 73.96%
西南区 2176.42万 5.25% 603.39万 6.46% 4.89% 72.28%

主要客户及供应商

您对此栏目的评价: 有用 没用 提建议
前5大客户:共销售了1.68亿元,占营业收入的40.60%
">
  • 客户第一名
  • 客户第二名
  • 客户第三名
  • 客户第四名
  • 客户第五名
  • 其他
客户名称 销售额(元) 占比
客户第一名
6637.29万 16.00%
客户第二名
3944.88万 9.51%
客户第三名
2446.60万 5.90%
客户第四名
2014.52万 4.86%
客户第五名
1797.04万 4.33%
前5大供应商:共采购了2277.78万元,占总采购额的40.45%
">
  • 供应商第一名
  • 供应商第二名
  • 供应商第三名
  • 供应商第四名
  • 供应商第五名
  • 其他
供应商名称 采购额(元) 占比
供应商第一名
619.22万 11.00%
供应商第二名
574.41万 10.20%
供应商第三名
488.69万 8.68%
供应商第四名
345.78万 6.14%
供应商第五名
249.68万 4.43%
前5大客户:共销售了1.56亿元,占营业收入的38.81%
">
  • 客户第一名
  • 客户第二名
  • 客户第三名
  • 客户第四名
  • 客户第五名
  • 其他
客户名称 销售额(元) 占比
客户第一名
8263.23万 20.53%
客户第二名
2512.43万 6.24%
客户第三名
1731.63万 4.30%
客户第四名
1729.65万 4.30%
客户第五名
1380.20万 3.43%
前5大供应商:共采购了2311.74万元,占总采购额的46.77%
">
  • 供应商第一名
  • 供应商第二名
  • 供应商第三名
  • 供应商第四名
  • 供应商第五名
  • 其他
供应商名称 采购额(元) 占比
供应商第一名
927.88万 18.77%
供应商第二名
545.03万 11.03%
供应商第三名
443.97万 8.98%
供应商第四名
207.03万 4.19%
供应商第五名
187.84万 3.80%
前5大客户:共销售了1.10亿元,占营业收入的37.19%
">
  • 客户第一名
  • 客户第二名
  • 客户第三名
  • 客户第四名
  • 客户第五名
  • 其他
客户名称 销售额(元) 占比
客户第一名
6154.25万 20.78%
客户第二名
1579.71万 5.33%
客户第三名
1189.83万 4.02%
客户第四名
1141.48万 3.85%
客户第五名
946.59万 3.20%
前5大供应商:共采购了1835.89万元,占总采购额的45.35%
">
  • 供应商第一名
  • 供应商第二名
  • 供应商第三名
  • 供应商第四名
  • 供应商第五名
  • 其他
供应商名称 采购额(元) 占比
供应商第一名
971.85万 24.01%
供应商第二名
431.83万 10.67%
供应商第三名
183.74万 4.54%
供应商第四名
129.69万 3.20%
供应商第五名
118.77万 2.93%
前5大客户:共销售了1.35亿元,占营业收入的43.01%
">
  • 客户第一名
  • 客户第二名
  • 客户第三名
  • 客户第四名
  • 客户第五名
  • 其他
客户名称 销售额(元) 占比
客户第一名
7097.85万 22.69%
客户第二名
2156.88万 6.89%
客户第三名
2081.86万 6.65%
客户第四名
1228.33万 3.93%
客户第五名
890.88万 2.85%
前5大供应商:共采购了1705.56万元,占总采购额的55.77%
">
  • 供应商第一名
  • 供应商第二名
  • 供应商第三名
  • 供应商第四名
  • 供应商第五名
  • 其他
供应商名称 采购额(元) 占比
供应商第一名
859.53万 28.10%
供应商第二名
330.23万 10.80%
供应商第三名
244.10万 7.98%
供应商第四名
157.10万 5.14%
供应商第五名
114.60万 3.75%
前5大客户:共销售了4869.52万元,占营业收入的32.62%
">
  • 客户1
  • 客户2
  • 客户3
  • 客户4
  • 客户5
  • 其他
客户名称 销售额(元) 占比
客户1
1242.92万 8.33%
客户2
1077.02万 7.21%
客户3
1006.36万 6.74%
客户4
904.88万 6.06%
客户5
638.34万 4.28%
前5大供应商:共采购了941.69万元,占总采购额的--
">
  • 供应商1
  • 供应商2
  • 供应商3
  • 供应商4
  • 供应商5
  • 其他
供应商名称 采购额(元) 占比
供应商1
469.75万 --%
供应商2
162.37万 --%
供应商3
123.84万 --%
供应商4
105.88万 --%
供应商5
79.84万 --%

董事会经营评述

  一、业务回顾和展望重要研发项目的进展及影响:
  公司秉承“广播仁爱·关注民生”的企业使命,坚持为人类的肝脏健康提供科学解决方案的初始梦想,坚定不移推动全球创新药物研发,向创新药企业转型。通过自主研发、合作开发和产业并购等方式,公司已形成以核苷(酸)类抗乙肝病毒药物为核心,覆盖乙肝、丙肝、脂肪肝、肝纤维化、肝癌、保肝护肝等肝脏健康全产品线的布局。
  报告期内,公司积极推进在研项目的研发进度,进展如下:
  (一)在研创新药进展
  1、乙肝治疗全球创新药GST-HG141召开临床启动会暨确定临床研究机构和研究负责人(PI)
  2020年1月,公司召开了乙肝治疗全球创新药GST-HG14... 查看全部▼

  一、业务回顾和展望重要研发项目的进展及影响:
  公司秉承“广播仁爱·关注民生”的企业使命,坚持为人类的肝脏健康提供科学解决方案的初始梦想,坚定不移推动全球创新药物研发,向创新药企业转型。通过自主研发、合作开发和产业并购等方式,公司已形成以核苷(酸)类抗乙肝病毒药物为核心,覆盖乙肝、丙肝、脂肪肝、肝纤维化、肝癌、保肝护肝等肝脏健康全产品线的布局。
  报告期内,公司积极推进在研项目的研发进度,进展如下:
  (一)在研创新药进展
  1、乙肝治疗全球创新药GST-HG141召开临床启动会暨确定临床研究机构和研究负责人(PI)
  2020年1月,公司召开了乙肝治疗全球创新药GST-HG141项目I期临床启动会,将由病毒性肝炎治疗领域著名专家、中华传染病学会等多家组织及杂志的委员、领事,原吉林大学第一医院副院长、肝胆胰内科主任牛俊奇教授担任GST-HG141片I期临床试验负责人(PI)。GST-HG141项目I期临床试验将由上海方达生物技术有限公司承接,承担受试者招募和筛选、临床试验项目管理和监查、临床生物样品分析、总结等事项。
  2、乙肝治疗全球创新药HBsAg抑制剂GST-HG131获得临床试验通知书
  2020年3月5日,公司获得乙肝治疗全球创新药HBsAg抑制剂GST-HG131的《临床试验通知书》,GST-HG131成为中国首个获批临床的乙肝表面抗原(HBsAg)抑制剂。临床前体外及体内药效学研究显示,GST-HG131能够诱导HBV-RNA降解,快速大幅降低HBsAg水平,且具有良好的安全性。GST-HG131核心化合物已申请PCT国际专利,其中国专利已获得授权。
  对公司未来经营产生不利影响的重要风险因素、公司经营存在的主要困难及公司拟采取的应对措施:
  1、行业政策风险
  近年来,国家引导和鼓励战略性新兴产业进行产业升级和结构优化,支持以创新为驱动的医药行业的发展,医药企业面临难得的创新发展机遇。但随着医疗体制改革的深入,国家带量采购政策的全面实施、一致性评价制度、两票制的推动,也对医药行业的药品研发、注册、生产与质量管理、销售、招标价格产生重大影响,短期对国内医药企业带来较大的经营压力和挑战,在一定程度上增加了经营风险。
  公司将根据行业政策的变化,积极探索和创新发展适合中国医疗水平、医改方向的经营模式,高效完成产品研发、注册、生产和质量控制、营销推广等全方面经营工作,确保公司能够适应外部经营环境变化,防范政策性风险。
  2、全球创新药开发风险
  新药研发具有周期长、投入大,风险高、收益大的特点。公司于2016年起在肝癌、非酒精性脂肪肝炎、治愈乙肝等领域立项5个全球一类新药研发项目,已陆续取得多项突破和成果,将有力提升公司研发创新能力及未来的市场竞争力。但在研发周期内,每年持续投入大额研发费用,短期内将对公司的经营业绩产生影响,同时还需承担新药研发失败的风险。
  创新研发,是医药行业未来发展的必然趋势。公司将积极组织实施产品研发工作,不断提升自主创新能力,提高研发水平,并严格按照国家政策、指导原则开展研发工作,对研发项目关键节点进行风险评估,降低过程风险。
  3、市场竞争风险
  虽然中国医药市场广阔而且发展潜力巨大,但是国际、国内企业竞相进入,叠加医保控费、带量采购等相关改革政策进一步深入推进,原材料成本、人力资源成本以及环保成本刚性上涨,市场竞争不断加剧,给医药企业带来持续的经营压力。
  公司将不断优化生产工艺,推进原料药制剂一体化基地建设,不断提高产品质量和综合成本优势,并且加强品牌建设,不断拓展多类型的销售网络渠道,以保持自身的竞争优势。
  4、并购重组风险
  公司积极推进并购和整合,通过并购的方式丰富产品线、拓展市场空间,并通过对被并购企业的深度整合降低成本、提高效率,在巩固原有的经营优势的同时,加快公司规模的扩大和市场竞争力的提升。但并购整合过程中可能存在一定的法律、政策、经营风险,收购成功后对公司的运营、管理方面也会提出更高的要求,同时并购可能产生较大金额的商誉,如并购未达到预期效益,存在商誉减值风险,从而对公司业绩造成不利影响。
  公司将谨慎甄选与公司定位相关联、具有互补性的优秀并购标的,组织专业团队,进行详尽的尽职调查,努力排查并购风险,同时对成功并购标的严格按照《公司法》、《证券法》、《上市规则》等相关法律法规的要求,不断完善其内部法人治理结构、健全内部管理制度,持续优化管理和运营。 收起▲